# ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

> **NCT04032847** · PHASE1,PHASE2 · TERMINATED · sponsor: **Achilles Therapeutics UK Limited** · enrollment: 27 (actual)

## Conditions studied

- Advanced Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** ATL001
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04032847
- **Lead sponsor:** Achilles Therapeutics UK Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-08
- **Primary completion:** 2024-09-26
- **Final completion:** 2024-09-26
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04032847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04032847, "ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04032847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*